chr4-105399137-G-A

Variant summary

Our verdict is Likely pathogenic. The variant received 8 ACMG points: 8P and 0B. PP5_Very_Strong

The NM_176869.3(PPA2):​c.683C>T​(p.Pro228Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000347 in 1,604,770 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★).

Frequency

Genomes: 𝑓 0.00043 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00034 ( 0 hom. )

Consequence

PPA2
NM_176869.3 missense

Scores

9
8
2

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:10

Conservation

PhyloP100: 9.48

Publications

14 publications found
Variant links:
Genes affected
PPA2 (HGNC:28883): (inorganic pyrophosphatase 2) The protein encoded by this gene is localized to the mitochondrion, is highly similar to members of the inorganic pyrophosphatase (PPase) family, and contains the signature sequence essential for the catalytic activity of PPase. PPases catalyze the hydrolysis of pyrophosphate to inorganic phosphate, which is important for the phosphate metabolism of cells. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]
PPA2 Gene-Disease associations (from GenCC):
  • sudden cardiac failure, infantile
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, Laboratory for Molecular Medicine

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_pathogenic. The variant received 8 ACMG points.

PP5
Variant 4-105399137-G-A is Pathogenic according to our data. Variant chr4-105399137-G-A is described in ClinVar as Pathogenic/Likely_pathogenic. ClinVar VariationId is 372226.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
PPA2NM_176869.3 linkc.683C>T p.Pro228Leu missense_variant Exon 8 of 12 ENST00000341695.10 NP_789845.1 Q9H2U2-1
PPA2NM_006903.4 linkc.596C>T p.Pro199Leu missense_variant Exon 7 of 11 NP_008834.3 Q9H2U2-3
PPA2NM_176866.2 linkc.377C>T p.Pro126Leu missense_variant Exon 4 of 8 NP_789842.2 Q9H2U2-6
PPA2NM_176867.3 linkc.185C>T p.Pro62Leu missense_variant Exon 2 of 6 NP_789843.2 Q9H2U2-4

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
PPA2ENST00000341695.10 linkc.683C>T p.Pro228Leu missense_variant Exon 8 of 12 1 NM_176869.3 ENSP00000343885.5 Q9H2U2-1

Frequencies

GnomAD3 genomes
AF:
0.000434
AC:
66
AN:
152018
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000193
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00164
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.0000945
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000471
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.000202
AC:
49
AN:
242474
AF XY:
0.000206
show subpopulations
Gnomad AFR exome
AF:
0.000127
Gnomad AMR exome
AF:
0.000217
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.0000484
Gnomad NFE exome
AF:
0.000332
Gnomad OTH exome
AF:
0.000338
GnomAD4 exome
AF:
0.000338
AC:
491
AN:
1452634
Hom.:
0
Cov.:
30
AF XY:
0.000328
AC XY:
237
AN XY:
722198
show subpopulations
African (AFR)
AF:
0.000122
AC:
4
AN:
32908
American (AMR)
AF:
0.000416
AC:
18
AN:
43272
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
25996
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39534
South Asian (SAS)
AF:
0.0000120
AC:
1
AN:
83632
European-Finnish (FIN)
AF:
0.0000383
AC:
2
AN:
52246
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5738
European-Non Finnish (NFE)
AF:
0.000407
AC:
452
AN:
1109232
Other (OTH)
AF:
0.000233
AC:
14
AN:
60076
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.436
Heterozygous variant carriers
0
25
50
76
101
126
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000434
AC:
66
AN:
152136
Hom.:
0
Cov.:
32
AF XY:
0.000403
AC XY:
30
AN XY:
74380
show subpopulations
African (AFR)
AF:
0.000193
AC:
8
AN:
41524
American (AMR)
AF:
0.00164
AC:
25
AN:
15266
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5184
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4806
European-Finnish (FIN)
AF:
0.0000945
AC:
1
AN:
10584
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.000471
AC:
32
AN:
67986
Other (OTH)
AF:
0.00
AC:
0
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.520
Heterozygous variant carriers
0
3
6
10
13
16
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000346
Hom.:
0
Bravo
AF:
0.000623
TwinsUK
AF:
0.000270
AC:
1
ALSPAC
AF:
0.00
AC:
0
ESP6500AA
AF:
0.000227
AC:
1
ESP6500EA
AF:
0.000698
AC:
6
ExAC
AF:
0.000247
AC:
30

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Pathogenic:6
-
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance:Likely pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance:Likely pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

May 21, 2021
Revvity Omics, Revvity
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 27, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 228 of the PPA2 protein (p.Pro228Leu). This variant is present in population databases (rs138215926, gnomAD 0.03%). This missense change has been observed in individual(s) with clinical features of PPA2-related conditions (PMID: 27523597). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 372226). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt PPA2 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects PPA2 function (PMID: 27523597). For these reasons, this variant has been classified as Pathogenic. -

-
Clinical Genetics, Academic Medical Center
Significance:Likely pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Jan 28, 2025
GeneDx
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Published functional studies demonstrate this variant has moderately reduced residual enzyme activity (PMID: 27523597); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 31705601, 27523597, 37249496, 37269378, 37869221, 34400813, 38582264, 30384889, Harris2024[preproof], 38893676) -

Sudden cardiac failure, infantile Pathogenic:2
May 06, 2021
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as likely pathogenic. The following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with sudden cardiac failure, alcohol-induced (MIM#617223) and sudden cardiac failure, infantile (MIM#617222). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from proline to leucine. (I) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD <0.01 for a recessive condition (v3) (66 heterozygotes, 0 homozygotes). (SP) 0502 - Missense variant with conflicting in silico predictions and uninformative conservation. (I) 0600 - Variant is located in the annotated inorganic pyrophosphatase domain (Pfam). (I) 0803 - This variant has limited previous evidence of pathogenicity in one family with four affected offspring with PPA2-related mitochondrial cardiomyopathy and sudden cardiac death. (PMID: 27523597). (SP) 0902 - This variant has moderate evidence for segregation with disease in a single family (PMID: 27523597). (SP) 1002 - This variant has moderate functional evidence supporting abnormal protein function. Pyrophosphatase activity was performed using cells in which this variant was introduced into the wild-type PPA2 sequence. This resulted in a 24%-28% decrease of residual activity of inorganic pyrophosphate substrate compared to wild-type. (PMID: 27523597) (SP) 0705 - No comparable missense variants have previous evidence for pathogenicity. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign -

Apr 01, 2025
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: PPA2 c.683C>T (p.Pro228Leu) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0002 in 242474 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in PPA2 causing Sudden Cardiac Failure, Infantile, allowing no conclusion about variant significance. c.683C>T has been reported in the presumed and confirmed compound heterozygous state in the literature in multiple individuals affected with clinical features of PPA2-related conditions (example, Kennedy_2016, Phoon_2020, Graham_2023, Gomez-Gonzalez_2024). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in 10%-<30% of normal activity (example, Kennedy_2016). The following publications have been ascertained in the context of this evaluation (PMID: 27523597, 31705601, 30384889, 37249496, 38582264). ClinVar contains an entry for this variant (Variation ID: 372226). Based on the evidence outlined above, the variant was classified as pathogenic. -

Sudden cardiac failure, alcohol-induced Pathogenic:1
Nov 23, 2016
OMIM
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:literature only

- -

Inborn genetic diseases Pathogenic:1
Apr 04, 2022
Ambry Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.683C>T (p.P228L) alteration is located in exon 8 (coding exon 8) of the PPA2 gene. This alteration results from a C to T substitution at nucleotide position 683, causing the proline (P) at amino acid position 228 to be replaced by a leucine (L). Based on data from gnomAD, the T allele has an overall frequency of 0.02% (58/273840) total alleles studied. The highest observed frequency was 0.03% (43/126958) of European (non-Finnish) alleles. This alteration was identified compound heterozygous with a second PPA2 variant and segregated with disease in several families in which affected individuals presented with acute heart failure or sudden cardiac death (Guimier, 2021; Kennedy, 2016). This amino acid position is highly conserved in available vertebrate species. E. coli strains expressing recombinant protein with the p.P228L variant showed 24-28% residual pyrophosphatase activity compared to wild type protein (Kennedy, 2016). The in silico prediction for this alteration is inconclusive. Based on the available evidence, this alteration is classified as pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.30
BayesDel_addAF
Uncertain
0.088
D
BayesDel_noAF
Pathogenic
0.20
CADD
Pathogenic
32
DANN
Uncertain
1.0
DEOGEN2
Uncertain
0.45
T;.;.;.;T
Eigen
Pathogenic
0.78
Eigen_PC
Pathogenic
0.78
FATHMM_MKL
Pathogenic
0.99
D
LIST_S2
Pathogenic
0.99
D;D;D;D;D
M_CAP
Uncertain
0.098
D
MetaRNN
Uncertain
0.42
T;T;T;T;T
MetaSVM
Uncertain
0.66
D
MutationAssessor
Pathogenic
4.3
H;.;.;.;.
PhyloP100
9.5
PrimateAI
Uncertain
0.56
T
PROVEAN
Pathogenic
-9.6
D;D;D;D;D
REVEL
Uncertain
0.55
Sift
Pathogenic
0.0
D;D;D;D;D
Sift4G
Pathogenic
0.0010
D;D;D;D;D
Polyphen
1.0
D;D;D;.;.
Vest4
0.84
MVP
0.89
MPC
0.49
ClinPred
1.0
D
GERP RS
5.9
Varity_R
0.97
gMVP
0.82
Mutation Taster
=0/100
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs138215926; hg19: chr4-106320294; COSMIC: COSV58994362; COSMIC: COSV58994362; API